Model Medicines
Model Medicines is a preclinical AI-first biotechnology company that uses its proprietary GALILEO platform to discover first-in-class small molecule therapeutics, advancing MDL-001 (a broad-spectrum antiviral targeting RdRp Thumb-1 across six viral families) and MDL-4102 (a selective BRD4 inhibitor) toward pharmaceutical licensing and government procurement partnerships.
- Company typePrivate
- Founded2019
- HeadquartersLa Jolla, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Model Medicines does
Model Medicines is a preclinical AI-first biotechnology company founded in 2019 and headquartered in La Jolla, California. The company develops its proprietary GALILEO AI Drug Discovery Platform, an end-to-end engine that combines target identification, ultra-large virtual screening (ULVS) at hundred-billion-compound scale, generative chemistry via the ChemPrint molecular geometric convolutional neural network, and predictive ADMET modeling through AmesNet for small molecule therapeutic discovery. The platform runs on Google Cloud infrastructure using lightweight CPU inference and has executed a record 325-billion-molecule virtual screen in 24 hours while generating over 52 trillion chemical entities.
The company operates a platform-plus-programs model anchored by two lead preclinical candidates: MDL-001, a first-in-class oral broad-spectrum antiviral targeting the conserved RdRp Thumb-1 allosteric pocket with activity demonstrated across six viral families (Orthomyxoviridae, Pneumoviridae, Coronaviridae, Flaviviridae, Kolmioviridae, and Hepadnaviridae, including influenza, RSV, SARS-CoV-2, HCV, HBV, and HDV), with IND submission targeted for late 2026; and MDL-4102, a first-in-class selective BRD4 inhibitor designed to overcome the dose-limiting thrombocytopenia that has halted prior pan-BET programs, with IND submission targeted for 2027. Scientific validation is provided by collaborations with Icahn School of Medicine at Mount Sinai (Dr. Adolfo García-Sastre, Dr. Kris White), UC San Diego (Dr. Davey Smith), and Scripps Research (Dr. Philippe Gallay).
The business model is pre-commercial. Model Medicines is pursuing licensing and co-development partnerships with pharmaceutical companies, with future revenue expected from upfront payments, development milestones, and royalties. The company is also positioning MDL-001 for U.S. government pandemic preparedness procurement via BARDA channels. To date, the company has raised approximately $22.1 million across funding rounds in 2021, 2024, and 2025, holds 15 patent families with protection through at least 2046, and operates with a lean team of 1-10 employees.
Model Medicines firmographics
Firmographics- Name
- Model Medicines
- Legal name
- Model Medicines, Inc.
- Website
- https://modelmedicines.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Model Medicines is a preclinical AI-first biotechnology company that uses its proprietary GALILEO platform to discover first-in-class small molecule therapeutics, advancing MDL-001 (a broad-spectrum antiviral targeting RdRp Thumb-1 across six viral families) and MDL-4102 (a selective BRD4 inhibitor) toward pharmaceutical licensing and government procurement partnerships.
- Ownership category
- akta.pro rank
Model Medicines industry classification
Industry- Product category
- AI Drug Discovery
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA), Cheminformatics & Molecular Modeling / CADD (HLAGAJAE), Lead Optimization & Preclinical Candidate Selection (HLAIALAB)
Keywords
Where Model Medicines is headquartered
LocationHeadquarters
- HQ city
- La Jolla
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Model Medicines business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
Revenue model
- Licensing and Co-development Agreements: Pre-revenue biotech seeking to license or co-develop preclinical assets including MDL-001 and MDL-4102 with pharmaceutical partners. Revenue would come from upfront payments, milestone payments, and royalties from partner development and commercialization.
- Pandemic Preparedness Contracts: Positioning MDL-001 as a tool for U.S. pandemic preparedness against future outbreak threats, potentially engaging government procurement and stockpiling arrangements.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels5 records
Model Medicines product offering
Product offeringCore offering
Model Medicines is an AI-first biotechnology company that uses its proprietary GALILEO AI Drug Discovery Platform to discover and develop first-in-class small molecule therapeutics targeting conserved biological choke points. The company is advancing two lead preclinical assets: MDL-001, an oral broad-spectrum antiviral targeting the RdRp Thumb-1 allosteric site across six viral families (respiratory and hepatic viruses), and MDL-4102, a selective BRD4 inhibitor for oncology, fibrosis, and cardiovascular disease. Revenue is generated through licensing and co-development partnerships with pharmaceutical companies.
Product overview
Model Medicines is an AI-first biotechnology company operating a platform-plus-programs model. The core technology is the GALILEO™ AI Drug Discovery Platform—an end-to-end engine combining target discovery, generative chemistry (ChemPrint), ultra-large virtual screening (ULVS), and predictive ADMET capabilities (AmesNet)—used to discover and advance first-in-class small molecule therapeutics. The company maintains two lead clinical candidates: MDL-001, a broad-spectrum antiviral targeting RdRp Thumb-1 with activity across six viral families (respiratory and hepatic viruses), and MDL-4102, a selective BRD4 inhibitor for oncology and fibrotic diseases. Additional programs include the VIROMME infectious disease spin-out. The platform has screened 325 billion molecules, generated 52+ trillion chemical entities, and discovered compounds with up to 15,000-fold specificity improvements. The company holds 15 patent families covering novel compositions of matter through at least 2046.
Differentiator
Problem solved
Functional benefit
Brands
- GALILEO: AI Drug Discovery Platform that generates biochemical data points from 3D protein structures, scaling to over 500 million constellation data points
- ChemPrint
- AmesNet
- ViroMME
Products and services
- MDL-001 First-in-class, oral, direct-acting, broad-spectrum antiviral targeting the RdRp Thumb-1 allosteric site of viral polymerases with nanomolar potency against six viral families. Developed for licensing or co-development with pharmaceutical partners for respiratory and hepatic viral infections.
- MDL-4102 First-in-class, highly potent, and selective BRD4 inhibitor with no measurable activity against BRD2 or BRD3, addressing dose-limiting thrombocytopenia of prior pan-BET inhibitors. Discovered through a 325-billion-molecule ultra-large virtual screen for licensing or co-development with pharmaceutical partners.
- GALILEO AI Drug Discovery Platform End-to-end AI engine that generates biochemical data points from 3D protein structures, enabling target discovery, generative chemistry, and preclinical development for AI-first drug discovery programs.
Quantifiable outcome
- 100% experimental hit rate identifying 12 novel broad-spectrum antiviral compounds from 52 trillion molecules explored
- +4 more outcomes
Companies that use Model Medicines
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles2 records
Model Medicines technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability7 records
Feature4 records
Model Medicines partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and key.
- Google CloudcoreStrategic partnership with Google Cloud infrastructure to execute the 325-billion-molecule virtual screening campaign in 2025. The GALILEO platform runs on Google Cloud using Google Kubernetes Engine, AMD EPYC CPU fleets, and Cloud Storage for molecular features and prediction results.
- Icahn School of Medicine at Mount SinaicoreResearch collaboration on MDL-001 broad-spectrum antiviral development. Includes Dr. Adolfo García-Sastre (Preclinical Development Advisor), Dr. Kris White (Preclinical Development Advisor), and Dr. Viviana Simon as collaborators on antiviral research across multiple viral families.
- Scripps ResearchcorePreclinical development collaboration including head-to-head 28-day in vivo study comparing MDL-001 to sofosbuvir. Dr. Philippe Gallay serves as Preclinical Advisor. Research focuses on HCV, HBV, and HDV including co-infection models.
- University of California, San DiegocoreResearch collaboration with Dr. Davey Smith (Lead Clinical Advisor, translational research virologist) on MDL-001 broad-spectrum antiviral validation. Includes preclinical efficacy studies and clinical development planning.
- BARDA / Rapid Response Partnership VehiclekeySelected to present at BARDA's Enabling Technologies Showcase at the Rapid Response Partnership Vehicle General Meeting. Positioning MDL-001 and GALILEO platform as tools for U.S. pandemic preparedness against future outbreak threats.
Scale indicators8 records
Recent moves6 records
Expansion highlights5 records
Model Medicines competitors and assessment
Company assessmentDirect peers
- Atomwise: AI-driven small molecule discovery using convolutional neural networks for structure-based virtual screening; directly comparable platform focused on hit identification through atomnet technology.
- Exscientia: AI-driven precision medicine company using CentaurAI platform for small molecule drug discovery; comparable end-to-end AI drug discovery capabilities with active pharma partnerships.
- Generate Biomedicines: Generative biology platform for programmable therapeutics; fellow Fierce 15 alumnus using AI/ML to accelerate novel drug design across multiple therapeutic areas.
- Insilico Medicine: Generative AI platform for small molecule drug discovery with end-to-end target ID through preclinical capabilities; shares the AI-first biotech positioning and Fierce 15 alumni status with Model Medicines.
- BenevolentAI: AI drug discovery company combining knowledge graphs with ML to identify novel targets and drug candidates; comparable platform-plus-pipeline approach to AI-driven therapeutic development.
- Isomorphic Labs: Alphabet-backed AI drug discovery company using deep learning for novel therapeutic design; comparable in applying large-scale generative AI to small molecule discovery.
- Recursion Pharmaceuticals: AI-driven drug discovery platform combining high-throughput biology with machine learning; directly comparable platform-plus-pipeline model and named alongside Model Medicines in Fierce Medtech Fierce 15 alumni.
- XtalPi: AI and robotics-driven drug discovery company combining quantum physics, cloud computing, and ML; directly comparable in applying AI to accelerate small molecule discovery at scale.
- Genesis Therapeutics: AI-driven small molecule drug discovery combining graph neural networks and generative models; directly comparable as a fellow Fierce 15 alumnus focused on first-in-class therapeutics discovery.
Broad incumbents
- Schrödinger, Inc. Established computational chemistry and molecular simulation platform with internal pipeline and software licensing business; offers comparable physics-based and ML drug discovery capabilities at greater scale.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Model Medicines social profiles
Digital presenceModel Medicines financial estimates
Financial estimateRevenue estimate
Valuation estimate
Model Medicines leadership team
Management profileNumber of profiles
Profiles5 records
Model Medicines funding detail
Funding detailFunding overview
Funding rounds4 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Model Medicines M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Model Medicines
What does Model Medicines do?
Model Medicines is an AI-first biotechnology company that uses its proprietary GALILEO AI Drug Discovery Platform to discover and develop first-in-class small molecule therapeutics targeting conserved biological choke points. The company is advancing two lead preclinical assets: MDL-001, an oral broad-spectrum antiviral targeting the RdRp Thumb-1 allosteric site across six viral families (respiratory and hepatic viruses), and MDL-4102, a selective BRD4 inhibitor for oncology, fibrosis, and cardiovascular disease. Revenue is generated through licensing and co-development partnerships with pharmaceutical companies.
Is Model Medicines a public or private company?
Model Medicines is a private company. It is classified as venture growth investor backed and is currently operating.
When was Model Medicines founded?
Model Medicines was founded in 2019. It employs 1 to 10 people.
Where is Model Medicines based?
Model Medicines is headquartered in La Jolla, United States, in the North America region.
How does Model Medicines make money?
Two revenue lines are on record. Licensing and Co-development Agreements are the primary driver. The others are pandemic Preparedness Contracts.
Who are Model Medicines's main competitors?
Direct peers on record are Atomwise, Exscientia, Generate Biomedicines, Insilico Medicine, BenevolentAI, Isomorphic Labs, Recursion Pharmaceuticals, XtalPi and Genesis Therapeutics. Schrödinger, Inc. is listed as a broad incumbent.
Does Model Medicines have an API?
No public API is recorded for Model Medicines.
What industry is Model Medicines in?
Model Medicines's product category is AI Drug Discovery. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery). Its NAICS code is 541714 and its SIC code is 8731.